FDA approves Genzyme's Fabrazyme®
Product is first treatment available in U.S. for people with Fabry Disease
28-Apr-2003 -
Genzyme General, a division of Genzyme Corp., announced today that the U.S. Food and Drug Administration has granted marketing approval for Fabrazyme® (agalsidase beta), an enzyme replacement therapy for Fabry disease. Fabrazyme is the first treatment approved in the United States for people ...
biologics
cardiovascular diseases
clinical trials
+17